214 related articles for article (PubMed ID: 38606105)
21. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.
Honeyman JN; Simon EP; Robine N; Chiaroni-Clarke R; Darcy DG; Lim II; Gleason CE; Murphy JM; Rosenberg BR; Teegan L; Takacs CN; Botero S; Belote R; Germer S; Emde AK; Vacic V; Bhanot U; LaQuaglia MP; Simon SM
Science; 2014 Feb; 343(6174):1010-4. PubMed ID: 24578576
[TBL] [Abstract][Full Text] [Related]
22. Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
Kang S; Magliocca J; Sellers M; Roccaro G; Zheng W; Pectasides M; Draper A; Guadagno J; El-Rayes B; Akce M
Oncol Res Treat; 2022; 45(7-8):430-437. PubMed ID: 35537414
[TBL] [Abstract][Full Text] [Related]
23. Hepatocellular Carcinoma, Fibrolamellar Variant: Diagnostic Pathologic Criteria and Molecular Pathology Update. A Primer.
Sergi CM
Diagnostics (Basel); 2015 Dec; 6(1):. PubMed ID: 26838800
[TBL] [Abstract][Full Text] [Related]
24. Enhanced cAMP-stimulated protein kinase A activity in human fibrolamellar hepatocellular carcinoma.
Riggle KM; Riehle KJ; Kenerson HL; Turnham R; Homma MK; Kazami M; Samelson B; Bauer R; McKnight GS; Scott JD; Yeung RS
Pediatr Res; 2016 Jul; 80(1):110-8. PubMed ID: 27027723
[TBL] [Abstract][Full Text] [Related]
25. Fibrolamellar hepatocellular carcinoma: a case report and gene analysis.
Watanabe A; Harimoto N; Saito H; Kawabata-Iwakawa R; Seki T; Muranushi R; Hoshino K; Hagiwara K; Ishii N; Tsukagoshi M; Igarashi T; Araki K; Ikota H; Ishige T; Mimori K; Shirabe K
Surg Case Rep; 2023 Sep; 9(1):168. PubMed ID: 37728655
[TBL] [Abstract][Full Text] [Related]
26. A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T
Rebucci-Peixoto M; Vienot A; Adotevi O; Jacquin M; Ghiringhelli F; de la Fouchardière C; You B; Maurina T; Kalbacher E; Bazan F; Meynard G; Clairet AL; Fagnoni-Legat C; Spehner L; Bouard A; Vernerey D; Meurisse A; Kim S; Borg C; Mansi L
Front Oncol; 2022; 12():957580. PubMed ID: 35928870
[TBL] [Abstract][Full Text] [Related]
27. Unique genomic profile of fibrolamellar hepatocellular carcinoma.
Cornella H; Alsinet C; Sayols S; Zhang Z; Hao K; Cabellos L; Hoshida Y; Villanueva A; Thung S; Ward SC; Rodriguez-Carunchio L; Vila-Casadesús M; Imbeaud S; Lachenmayer A; Quaglia A; Nagorney DM; Minguez B; Carrilho F; Roberts LR; Waxman S; Mazzaferro V; Schwartz M; Esteller M; Heaton ND; Zucman-Rossi J; Llovet JM
Gastroenterology; 2015 Apr; 148(4):806-18.e10. PubMed ID: 25557953
[TBL] [Abstract][Full Text] [Related]
28. Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.
Abou-Alfa GK; Mayer R; Venook AP; O'Neill AF; Beg MS; LaQuaglia M; Kingham PT; Kobos R; Basturk O; Brennan C; Yopp A; Harding JJ; Leong S; Crown J; Hoti E; Leonard G; Ly M; Bradley M; Valentino E; Markowitz D; Zukiwski A; Ren K; Gordan JD
Oncologist; 2020 Dec; 25(12):e1837-e1845. PubMed ID: 32154962
[TBL] [Abstract][Full Text] [Related]
29. DNAJB1-PRKACA-positive metastatic fibrolamellar carcinoma with unknown primary in a pediatric patient.
Balbeur S; Dumortier A; Mergen J; Libbrecht L; Torbenson M; Boulanger C; de Ville de Goyet M; Van Damme A; Brichard B
Pediatr Blood Cancer; 2020 Feb; 67(2):e28060. PubMed ID: 31736218
[TBL] [Abstract][Full Text] [Related]
30. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature.
Alshareefy Y; Shen CY; Prekash RJ
Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175
[TBL] [Abstract][Full Text] [Related]
31. DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma.
Ma RK; Tsai PY; Farghli AR; Shumway A; Kanke M; Gordan JD; Gujral TS; Vakili K; Nukaya M; Noetzli L; Ronnekleiv-Kelly S; Broom W; Barrow J; Sethupathy P
PLoS Genet; 2024 Mar; 20(3):e1011216. PubMed ID: 38512964
[TBL] [Abstract][Full Text] [Related]
32. DnaJ-PKAc fusion induces liver inflammation in a zebrafish model of fibrolamellar carcinoma.
de Oliveira S; Houseright RA; Korte BG; Huttenlocher A
Dis Model Mech; 2020 Apr; 13(4):. PubMed ID: 32102783
[TBL] [Abstract][Full Text] [Related]
33. Molecular testing for the clinical diagnosis of fibrolamellar carcinoma.
Graham RP; Yeh MM; Lam-Himlin D; Roberts LR; Terracciano L; Cruise MW; Greipp PT; Zreik RT; Jain D; Zaid N; Salaria SN; Jin L; Wang X; Rustin JG; Kerr SE; Sukov WR; Solomon DA; Kakar S; Waterhouse E; Gill RM; Ferrell L; Alves VA; Nart D; Yilmaz F; Roessler S; Longerich T; Schirmacher P; Torbenson MS
Mod Pathol; 2018 Jan; 31(1):141-149. PubMed ID: 28862261
[TBL] [Abstract][Full Text] [Related]
34. Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors.
Chen KY; Popovic A; Hsiehchen D; Baretti M; Griffith P; Bista R; Baghdadi A; Kamel IR; Simon SM; Migler RD; Yarchoan M
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358766
[TBL] [Abstract][Full Text] [Related]
35. A case report of fibrolamellar hepatocellular carcinoma, with particular reference to preoperative diagnosis, value of molecular genetic diagnosis, and cell origin.
Takahashi A; Imamura H; Ito R; Kawano F; Gyoda Y; Ichida H; Yoshioka R; Mise Y; Fukumura Y; Sano K; Saiura A
Surg Case Rep; 2021 Sep; 7(1):208. PubMed ID: 34533614
[TBL] [Abstract][Full Text] [Related]
36. Fibrolamellar carcinoma: An entity all its own.
O'Neill AF; Church AJ; Perez-Atayde AR; Shaikh R; Marcus KJ; Vakili K
Curr Probl Cancer; 2021 Aug; 45(4):100770. PubMed ID: 34272087
[TBL] [Abstract][Full Text] [Related]
37. AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas.
Bunse L; Rupp AK; Poschke I; Bunse T; Lindner K; Wick A; Blobner J; Misch M; Tabatabai G; Glas M; Schnell O; Gempt J; Denk M; Reifenberger G; Bendszus M; Wuchter P; Steinbach JP; Wick W; Platten M
Neurol Res Pract; 2022 May; 4(1):20. PubMed ID: 35599302
[TBL] [Abstract][Full Text] [Related]
38. Multiomic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinoma.
Francisco AB; Kanke M; Massa AP; Dinh TA; Sritharan R; Vakili K; Bardeesy N; Sethupathy P
JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35482409
[TBL] [Abstract][Full Text] [Related]
39. Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1-Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma.
Jewell ML; Gibson JR; Guy CD; Hyun J; Du K; Oh SH; Premont RT; Hsu DS; Ribar T; Gregory SG; Diehl AME
Am J Pathol; 2020 Jan; 190(1):93-107. PubMed ID: 31669305
[TBL] [Abstract][Full Text] [Related]
40. Current Advances in the Treatment of Fibrolamellar Carcinoma of Liver.
Gummadi J; Wang X; Xie C
J Hepatocell Carcinoma; 2023; 10():745-752. PubMed ID: 37215364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
